HBOT for Fibromyalgia | NorCal Hyperbarics Concord, CA

Fibromyalgia is a chronic pain disorder characterized by widespread musculoskeletal pain, profound fatigue, non-restorative sleep, cognitive dysfunction ("fibro fog"), and often mood disturbances. It affects an estimated 4 million Americans — approximately 2% of the adult population — and is diagnosed predominantly in women, though it affects all sexes and ages. Fibromyalgia is the second most common condition seen by rheumatologists after osteoarthritis.

The modern understanding of fibromyalgia positions it as a disorder of central sensitization: a state in which the central nervous system's pain-processing circuits become dysregulated, amplifying pain signals far beyond what the underlying tissue stimulus would normally produce. This explains fibromyalgia's characteristic allodynia (pain from normally non-painful stimuli) and hyperalgesia (exaggerated pain from mildly painful stimuli), its co-occurrence with other central sensitivity syndromes (including irritable bowel syndrome, interstitial cystitis, and headache disorders), and its resistance to purely peripheral pain treatments.

Fibromyalgia is often co-diagnosed with other conditions including chronic fatigue syndrome, Long COVID, PTSD, and mood disorders — sharing overlapping neurobiological mechanisms with all of these. In the Bay Area, where awareness of evidence-based integrative approaches is high, fibromyalgia patients are often actively seeking treatments that address the biological roots of their condition rather than solely managing symptoms with medications that carry their own side-effect burdens.

For decades, fibromyalgia was dismissed as a psychological condition — but modern neuroimaging has fundamentally changed that understanding. SPECT and fMRI studies consistently document measurable brain abnormalities in fibromyalgia patients, most notably reduced blood flow in the thalamus (a critical pain relay center) and prefrontal cortex, and increased activity in brain regions associated with pain amplification. These imaging findings establish fibromyalgia as a condition with a physical, neurobiological substrate — and one that HBOT is positioned to address.

The pivotal clinical evidence for HBOT in fibromyalgia is a randomized controlled trial by Efrati and colleagues published in PLOS ONE in 2015. The trial compared HBOT (40 sessions at 2.0 atmospheres) to a control condition in women with fibromyalgia and found: significant reductions in pain scores and pain sensitivity, improvement in fatigue and sleep quality, meaningful quality-of-life improvements on validated fibromyalgia outcome measures, and — critically — normalization of SPECT cerebral blood flow patterns in the thalamus and frontal cortex that corresponded directly to the degree of clinical improvement. Approximately 70% of patients achieved significant clinical benefit. This was not a study of symptom masking; it was evidence of brain repair.

The mechanism is consistent with HBOT's broader actions: correcting the cerebral hypoperfusion that impairs pain-inhibitory signaling in the thalamus and prefrontal cortex, reducing neuroinflammation that amplifies pain sensitization, supporting mitochondrial function in hypoxic brain tissue, and promoting neuroplasticity in pain-modulating circuits. Dr. Toth designs fibromyalgia protocols based on the published evidence (typically 40 sessions), coordinated with the patient's rheumatologist or pain management physician.